Hemolytic-Uremic Syndrome

Effect of a New Antithrombotic Agent (Defibrotide) in Acute Renal Failure Due to Thrombotic Microangiopathy

“…Prolonged anu ria. hypertension and marked neurological manifesta tions are signs of poor prognosis both for the recovery of renal function and patient survival [10]. Many therapeutic approaches have been employed, using heparin [II 13], streptokinase [14], antithrombin III [15], and platelet aggregation inhibitors [16,17].…”

A New Antithrombotic Agent in the Treatment of Acute Renal Failure Due to Hemolytic-Uremic Syndrome and Thrombotic Thrombocytopenic Purpura

“…The etiology and pathogenesis of the two conditions are still unclear. It has been suggested [1] that a process of intravascular coagulation plays a role in the development of renal lesions, and thrombotic lesions are seen in the glomeruli and vessels up to the arcuate arteries. These findings have prompted numerous therapeutic attempts using heparin, urokinase, streptokinase, and platelet aggregation inhibitors, but the efficacy of these ap proaches is difficult to assess.…”

Recurrent Hemolytic Uremic Syndrome and Metastatic Malignancy

“…In a review article of HUS, Gold stein et al [12] mentioned such an association referring to the study of Lohrman et al [13] in which metastatic carcinoma was associated with MAHA but not HUS. Among previous observations of HUS in association with malignancy we found only 3 reports where the syn drome occurred in the absence of chemotherapy.…”

“…Localized intravascular coagulation in the kidney or epithelial cell injury have both been proposed as crucial events in the pathogenesis of HUS [ 12,14]. How neopla sia could induce either of these is largely unknown.…”